FDA Commissioner: Patient Safety Must Be Prioritized Over Job Creation
Dr. Hamburg was joined by Paul Glover of Health Canada and Guido Rasi of the European Medicines Agency at the Drug Information Association's 48th annual meeting.
The FDA was recently scrutinized by Congressional members who believe the agency has impeded job creation by shutting down plants with quality control problems. Dr. Hamburg stressed quality concerns, such as glass shards and metal fractures in tobacco products, could not be ignored by the FDA and other regulators.
Mr. Glover added a universal reporting mechanism could more quickly alert regulators about adverse events and promote patient safety around the world.
More Articles on Patient Safety:AHRQ 2011 State Snapshots Spotlight Healthcare Quality, Population Health
© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
- 5 things to know about Pres. Trump's executive order addressing the ACA
- Should Medicare allow total joints in ASCs? Q&A with Drs. Barry Waldman, Derek Johnson
- 84% of medical personnel are unsure of MACRA's requirements, survey finds: 3 takeaways
- Healthcare plan vanishes from WhiteHouse.gov after President Donald Trump takes oath
- Christ Hospital's dispute with St. Elizabeth Healthcare over $24M ASC may wage on for years